EP1931352B1 - Tlr-agonisten - Google Patents

Tlr-agonisten Download PDF

Info

Publication number
EP1931352B1
EP1931352B1 EP06813535.9A EP06813535A EP1931352B1 EP 1931352 B1 EP1931352 B1 EP 1931352B1 EP 06813535 A EP06813535 A EP 06813535A EP 1931352 B1 EP1931352 B1 EP 1931352B1
Authority
EP
European Patent Office
Prior art keywords
compound
alkyl
substituted
aryl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP06813535.9A
Other languages
English (en)
French (fr)
Other versions
EP1931352A4 (de
EP1931352A2 (de
Inventor
Dennis A. Carson
Kenji Takabayashi
Howard B. Cottam
Michael Chan
Christina C. N. Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP1931352A2 publication Critical patent/EP1931352A2/de
Publication of EP1931352A4 publication Critical patent/EP1931352A4/de
Application granted granted Critical
Publication of EP1931352B1 publication Critical patent/EP1931352B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Definitions

  • PAMPs pathogen associated molecular patterns
  • PAMPs include peptidoglycans, lipotechoic acids from gram-positive cell walls, the sugar mannose (which is common in microbial carbohydrates but rare in humans), bacterial DNA, doublestranded RNA from viruses, and glucans from fungal cell walls.
  • TLRs Toll-like Receptors
  • TLR7 and TLR9 recognize and respond to imiquimod and immunostimulatory CpG oligonucleotides (ISS-ODN), respectively.
  • the synthetic immunomodulator R-848 activates both TLR7 and TLR8. While TLR stimulation initiates a common signaling cascade (involving the adaptor protein MyD88, the transcription factor NF-kB, and pro-inflammatory and effector cytokines), certain cell types tend to produce certain TLRs. For example, TLR7 and TLR9 are found predominantly on the internal faces of endosomes in dendritic cells (DCs) and B lymphocytes (in humans; mouse macrophages express TLR7 and TLR9). TLR8, on the other hand, is found in human blood monocytes. (See Hornung et al., J. Immunol, 168:4531-4537 (2002 )).
  • Interferons are also involved in the efficient induction of an immune response, especially after viral infection ( Brassard et al., J. Leukoc Biol, 71:568-581 (2002 )). However, many viruses produce a variety of proteins that block interferon production or action at various levels. Antagonism of interferon is believed to be part of a general strategy to evade innate, as well as adaptive immunity. (See Levy et al., Cytokine Growth Factor Rev, 12:143-156 (2001 ).) While TLR agonists (TLR-L) may be sufficiently active for some use of treatment, in some instances the microbial interferon antagonists could mitigate the adjuvant effects of synthetic TLR-L.
  • EP 1 035 123 discloses heterocyclic compounds having inducing activity for the biosynthesis of interferon in a living body.
  • the heterocyclic compounds are useful for medicines such as antiviral agents, anticancer agents and therapeutic agents for immunologic disease.
  • Adenine compounds and the use thereof are presented in EP 1 550 662 .
  • the adenine compounds are administered topically and are useful as a prophylactic or therapeutic agents for viral disease, allergic disease, etc.
  • US 2005/0004144 describes a non-toxic combination of synthetic immuno-stimulatory agents, useful for activating the immune system of a mammal and treating diseases such cancer and autoimmune disease.
  • the agents include TLR-ligands and ligand analogs which induce interferon production, in combination with inhibitors of inosine monophosphate dehydrogenase, that further enhance the induction of interferon production.
  • the present invention provides for TLR agonist conjugates (compounds) and compositions, as well as their therapeutic use.
  • the compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore.
  • the compounds of the invention include a pharmacophore covalently bound to an auxiliary group. Accordingly there is provided a compound of the invention which is a compound of formula (I):
  • the auxiliary groups can include organic molecules, composed of carbon, oxygen, hydrogen, nitrogen, sulfur, phosphorous atoms. These groups are not harmful to body tissues ( e.g., they are non-toxic, and/or do not cause inflammation).
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising at least one compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.
  • the invention provides a composition or compound for use in preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the activity of TLR agonists is implicated and its action is desired, comprising administering to a mammal in need of such therapy, an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • pathological conditions or symptoms that are suitable for treatment include cancers, treatment for bacterial or viral diseases, treating autoimmune diseases, and treating Crohn's Disease.
  • the compounds of the invention can also be used as or to prepare vaccines against bacteria, viruses, cancer cells, cancer specific peptides, enhancers of monoclonal antibodies against cancer, a CNS stimulant, or for biodefense.
  • the invention provides a compound of formula (I) for use in medical therapy (e.g., for use as an anti-cancer agent, treatment for bacterial diseases, treatment for viral diseases, such as hepatitis C and hepatitis B, Crohn's Disease, and as therapeutic agents for treating immunologic disease). Furthermore, it is suggested that compounds of formula (I) will prevent carcinogenesis by hepatitis C and hepatitis B, as well as the use of a compound of formula (I) for the manufacture of a medicament useful for the treatment of cancer, viral diseases, Crohn's Disease, and immunologic disorders in a mammal, such as a human.
  • medical therapy e.g., for use as an anti-cancer agent, treatment for bacterial diseases, treatment for viral diseases, such as hepatitis C and hepatitis B, Crohn's Disease, and as therapeutic agents for treating immunologic disease.
  • compounds of formula (I) will prevent carcinogenesis by hepatitis C and hepatitis B, as well
  • the present invention provides a compound of formula (I) or composition comprising the compound of formula (I) for use in treating a viral infection in a mammal by administering a TLR agonist compound of formula (I).
  • the viral infection can be caused by an RNA virus, a product of the RNA virus that acts as a TLR agonist and/or a DNA virus.
  • a specific DNA virus for treatment is the Hepatitis B virus.
  • the present invention provides a compound of formula (I) or composition comprising the compound of formula (I) for use in treating cancer by administering an effective amount of a TLR agonist compound of formula (I).
  • the cancer can be an interferon sensitive cancer, such as, for example, a leukemia, a lymphoma, a myeloma, a melanoma, or a renal cancer.
  • the present invention provides a compound of formula (I) or composition comprising the compound of formula (I) for use in treating an autoimmune disease by administering a therapeutically effective amount of a TLR agonist compound of formula (I) or a pharmaceutically acceptable salt of such a compound.
  • a specific autoimmune disease is Multiple Sclerosis, lupus, rheumatoid arthritis and the like.
  • the present invention provides a compound of formula (I) or composition comprising the compound of formula (I) for use in treating Crohn's Disease by administering a TLR agonist compound of formula (I).
  • the TLR agonists can be a homofunctional TLR agonist polymer and can consist of a TLR-7 agonist or a TLR-8 agonist.
  • the TLR7 agonist can be a 7-thia-8-oxoguanosinyl (TOG) moiety, a 7-deazaguanosinyl (7DG) moiety, a resiquimod moiety, or an imiquimod moiety.
  • the TLR8 agonist can be a resiquimod moiety.
  • the TLR agonist is a heterofunctional TLR agonist polymer.
  • the heterofunctional TLR agonist polymer can include a TLR-7 agonist and a TLR-8 agonist or a TLR-9 agonist or all three agonists.
  • the heterofunctional TLR agonist polymer can include a TLR-8 agonist and a TLR-9 agonist.
  • the invention also provides processes and intermediates disclosed herein that are useful for preparing compounds of formula (I) or salts thereof.
  • the auxiliary group R 3 is a protein or a peptide(polymers of amino acids), e.g ., dipeptides or tripeptides, and the like
  • the compounds of the invention can be prepared using compounds having formula (IA): where X is a group that can react to form a bond to the linking group or can react to form a bond to the auxiliary group R 3 .
  • X is a group that can react to form a bond to the linking group or can react to form a bond to the auxiliary group R 3 .
  • a specific group of compounds having formula (IA) are disclosed in U.S. Patent No. 6,329,381 .
  • halo is fluoro, chloro, bromo, or iodo.
  • Alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as "propyl” embraces only the straight chain radical, a branched chain isomer such as "isopropyl” being specifically referred to.
  • Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic.
  • Heteroaryl encompasses a radical attached via a ring carbon of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X) wherein X is absent or is H, O, (C 1 -C 4 )alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a benz-derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto.
  • Processes for preparing compounds of formula I or for preparing intermediates useful for preparing compounds of formula I are provided as further embodiments of the invention.
  • Intermediates useful for preparing compounds of formula I are also provided as further embodiments of the invention.
  • salts may be appropriate.
  • acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, ⁇ -ketoglutarate, and ⁇ -glycerophosphate.
  • Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
  • Acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
  • a sufficiently basic compound such as an amine
  • a suitable acid affording a physiologically acceptable anion.
  • Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
  • Alkyl includes straight or branched C 1-10 alkyl groups, e.g., methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, 1-methylpropyl, 3-methylbutyl, hexyl, and the like.
  • Lower alkyl includes straight or branched C 1-6 alkyl groups, e.g., methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, and the like.
  • C 1-6 alkyl groups e.g., methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, and the like.
  • alkylene refers to a divalent straight or branched hydrocarbon chain (e.g . ethylene -CH 2 -CH 2 -).
  • C 3-7 cycloalkyl includes groups such as, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, and alkyl-substituted C 3-7 cycloalkyl group, preferably straight or branched C 1-6 alkyl group such as methyl, ethyl, propyl, butyl or pentyl, and C 5-7 cycloalkyl group such as, cyclopentyl or cyclohexyl, and the like.
  • Lower alkoxy includes C 1-6 alkoxy groups, such as methoxy, ethoxy or propoxy, and the like.
  • Lower alkanoyl includes C 1-6 alkanoyl groups, such as formyl, acetyl, propanoyl, butanoyl, pentanoyl or hexanoyl, and the like.
  • C 7-11 aroyl includes groups such as benzoyl or naphthoyl;
  • Lower alkoxycarbonyl includes C 2-7 alkoxycarbonyl groups, such as methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl , and the like.
  • Lower alkylamino group means amino group substituted by C 1-6 alkyl group, such as, methylamino, ethylamino, propylamino, butylamino, and the like.
  • Di(lower alkyl)amino group means amino group substituted by the same or different and C 1-6 alkyl group (e.g. dimethylamino, diethylamino, ethylmethylamino).
  • Lower alkylcarbamoyl group means carbamoyl group substituted by C 1-6 alkyl group (e.g. methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, butylcarbamoyl).
  • Di(lower alkyl)carbamoyl group means carbamoyl group substituted by the same or different and C 1-6 alkyl group (e.g. dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl).
  • Halogen atom means halogen atom such as fluorine atom, chlorine atom, bromine atom or iodine atom.
  • Aryl refers to a C 6-10 monocyclic or fused cyclic aryl group, such as phenyl, indenyl, or naphthyl, and the like.
  • Heterocyclic refers to monocyclic saturated heterocyclic groups, or unsaturated monocyclic or fused heterocyclic group containing at least one heteroatom, e.g ., 0-3 nitrogen atoms (-NR d -), 0-1 oxygen atom (-0-), and 0-1 sulfur atom (-S-).
  • saturated monocyclic heterocyclic group includes 5 or 6 membered saturated heterocyclic group, such as tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperidyl, piperazinyl or pyrazolidinyl.
  • Non-limiting examples of unsaturated monocyclic heterocyclic group includes 5 or 6 membered unsaturated heterocyclic group, such as furyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thienyl, pyridyl or pyrimidinyl.
  • Non-limiting examples of unsaturated fused heterocyclic groups includes unsaturated bicyclic heterocyclic group, such as indolyl, isoindolyl, quinolyl, benzothizolyl, chromanyl, benzofuranyl, and the like.
  • heterocyclic rings include 5 or 6 membered saturated heterocyclic rings, such as 1-pyrrolidinyl, 4-morpholinyl, 1-piperidyl, 1-piperazinyl or 1-pyrazolidinyl, 5 or 6 membered unsaturated heterocyclic rings such as 1-imidazolyl , and the like.
  • the alkyl, aryl, heterocyclic groups of R 1 can be optionally substituted with one or more substituents, wherein the substituents are the same or different, and include lower alkyl; cycloalkyl, hydroxyl; hydroxy C 1-6 alkylene, such as hydroxymethyl, 2-hydroxyethyl or 3-hydroxypropyl; lower alkoxy; C 1-6 alkoxy C 1-6 alkyl, such as 2-methoxyethyl, 2-ethoxyethyl or 3-methoxypropyl; amino; alkylamino; dialkyl amino; cyano; nitro; acyl; carboxyl; lower alkoxycarbonyl; halogen; mercapto; C 1-6 alkylthio, such as, methylthio, ethylthio, propylthio or butylthio; substituted C 1-6 alkylthio, such as methoxyethylthio, methylthioethylthio, hydroxyeth
  • the alkyl, aryl, heterocyclic groups of R 2 can be optionally substituted with one or more substituents, wherein the substituents are the same or different, and include hydroxyl; C 1-6 alkoxy, such as methoxy, ethoxy or propoxy; carboxyl; C 2-7 alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl and halogen.
  • substituents are the same or different, and include hydroxyl; C 1-6 alkoxy, such as methoxy, ethoxy or propoxy; carboxyl; C 2-7 alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl or propoxycarbonyl and halogen.
  • n is1, 2, 3 or 4.
  • the alkyl, aryl, heterocyclic groups of R c can be optionally substituted with one or more substituents, wherein the substituents are the same or different, and include C 3-6 cycloalkyl; hydroxyl; C 1-6 alkoxy; amino; cyano; aryl; substituted aryl, such as 4-hydroxyphenyl, 4-methoxyphenyl, 4-chlorophenyl or 3,4-dichlorophenyl; nitro and halogen.
  • the heterocyclic ring formed together with R c and R 1 and the nitrogen atom to which they are attached can be optionally substituted with one or more substituents, wherein the substituents are the same or different, and include C 1-6 alkyl; hydroxy C 1-6 alkylene; C 1-6 alkoxy C 1-6 alkylene; hydroxyl; C 1-6 alkoxy; and cyano.
  • amino acid as used herein, comprises the residues of the natural amino acids (e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D or L form, as well as unnatural amino acids (e.g.
  • the term also comprises natural and unnatural amino acids bearing a conventional amino protecting group (e.g.
  • acetyl or benzyloxycarbonyl as well as natural and unnatural amino acids protected at the carboxy terminus (e.g. as a (C 1 -C 6 )alkyl, phenyl or benzyl ester or amide; or as an -methylbenzyl amide).
  • suitable amino and carboxy protecting groups are known to those skilled in the art (See for example, T.W. Greene, Protecting Groups In Organic Synthesis; Wiley: New York, 1981, and references cited therein).
  • An amino acid can be linked to the remainder of a compound of formula I through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of cysteine.
  • TLR toll-like receptor
  • PAMPs pathogen associated molecular patterns
  • TLR agonist refers to a molecule that binds to a TLR and antagonizes the receptor.
  • Synthetic TLR agonists are chemical compounds that are designed to bind to a TLR and activate the receptor.
  • Exemplary novel TLR agonists provided herein include "TLR-7 agonist” "TLR-8 agonist” and "TLR-9 agonist.”
  • a specific value for X 1 is a sulfur atom, an oxygen atom or -NR c -.
  • Another specific X 1 is a sulfur atom.
  • Another specific X 1 is an oxygen atom.
  • Another specific X 1 is -NR c -.
  • Another specific X 1 is -NH-.
  • R c is hydrogen, C 1-4 alkyl or substituted C 1-4 alkyl.
  • R 1 and R c taken together is when they form a heterocyclic ring or a substituted heterocyclic ring.
  • R 1 and R c taken together is substituted or unsubstituted morpholino, piperidino, pyrrolidino, or piperazino ring.
  • R 1 is hydrogen, C 1-4 alkyl, or substituted C 1-4 alkyl.
  • R 1 is 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, ethoxymethyl, 2-ethoxyethyl, methylthiomethyl, 2-methylthioethyl, 3-methylthiopropyl, 2-fluotoethyl, 3-fluoropropyl, 2,2,2-trifluoroethyl, cyanomethyl, 2-cyanoethyl, 3-cyanopropyl, methoxycarbonylmethyl, 2-methoxycarbonylethyl, 3-methoxycarbonylpropyl, benzyl, phenethyl, 4-pyridylmethyl, cyclohexylmethyl, 2-thienylmethyl; 4-methoxyphenylmethyl, 4-hydroxyphenylmethyl, 4-fluorophenylmethyl, or 4-chlorophen
  • R 1 is hydrogen, CH 3 -, CH 3 -CH 2 -, CH 3 CH 2 CH 2 -, hydroxyC 1-4 alkylene, or C 1-4 alkoxyC 1-4 alkylene.
  • R 1 is hydrogen, CH 3 -, CH 3 -CH 2 -, CH 3 -O-CH 2 CH 2 - or CH 3 -CH 2 -O-CH 2 CH 2 -.
  • R 2 is hydrogen, halogen, or C 1-4 alkyl.
  • R 2 is hydrogen, chloro, bromo, CH 3 -, or CH 3 -CH 2 -.
  • substituents for substitution on the alkyl, aryl or heterocyclic groups are hydroxy, C 1-6 alkyl, hydroxyC 1-6 alkylene, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkylene, C 3-6 cycloalkyl, amino, cyano, halogen, or aryl.
  • a specific value for X 2 is a bond or a chain having up to about 24 atoms; wherein the atoms are selected from the group consisting of carbon, nitrogen, sulfur, non-peroxide oxygen, and phosphorous.
  • X 2 is a bond or a chain having from about 4 to about 12 atoms.
  • X 2 is a bond or a chain having from about 6 to about 9 atoms.
  • Another specific value for X 2 is or or Another specific value for X 2 is
  • the auxiliary group R 3 is a protein or a peptide.
  • a specific peptide has from 2 to about 20 amino acid residues.
  • Another specific peptide has from 10 to about 20 amino acid residues.
  • Specific compounds of the invention have the general formula IA-L-A 1 ; IA-L-(A 1 ) 2 ; IA-L-A 1 -A 1 ; IA-L-A 1 -L-A 1 ; (IA) 2 -L-A 1 -A 1 ; (IA) 2 -L-A 1 -L-A 1 ; (IA) 2 -L-A 1 ; or (IA) 2 -L-(A 1 ) 2 ; wherein IA is as disclosed herein; L is absent or is a linking group; and each A 1 group independently represents an auxiliary group R 3 according to the invention.
  • the viral infection is caused by a coronavirus that causes Severe Acute Respiratory Syndrome (SARS), a Hepatitis B virus, or a Hepatitis C Virus.
  • SARS Severe Acute Respiratory Syndrome
  • Hepatitis B virus a Hepatitis B virus
  • Hepatitis C Virus a Hepatitis C virus
  • the viral infection is caused by a coronavirus that causes Severe Acute Respiratory Syndrome (SARS), a Hepatitis B virus, or a Hepatitis C Virus.
  • SARS Severe Acute Respiratory Syndrome
  • Hepatitis B virus a Hepatitis B virus
  • Hepatitis C Virus a coronavirus that causes Severe Acute Respiratory Syndrome
  • Specific cancers that can be treated include melanoma, superficial bladder cancer, actinic keratoses, intraepithelial neoplasia, and basal cell skin carcinoma, squamous, and the like.
  • the invention includes the use for treatment for a precancerous condition such as, for example, actinic keratoses or intraepithelial neoplasia, familial polyposis (polyps), cervical dysplasia, cervical cancers, superficial bladder cancer, and any other cancers associated with infection (e.g ., lymphoma Karposi's sarcoma, or leukemia); and the like.
  • Non limiting examples of the pathological conditions or symptoms that can be treated include viral diseases, cancer, inflammatory diseases of the gastrointestinal tract, brain, skin, joints, and other tissues.
  • the auxiliary groups R 3 according to the invention are believed to enhance the drug activity of the pharmacophore (compounds of formula (I)) by (a) helping to direct the pharmacophore to the receptor within the endosomes of target cells; (b) by enhancing signal transduction induced by the pharmacophore, by cross-linking the receptor; and/or (c) the pharmacophore can enhance the response to the auxiliary group ( e.g ., immune response).
  • the auxiliary group R 3 according to the invention should form generally stable bonds with the pharmacophore, and do not act as prodrugs.
  • IMPDH inosine monophosphate dehydrogenase
  • an IMPDH inhibitor refers to an inhibitor of the enzyme inosine monophosphate dehydrogenase.
  • IMPDH inhibitors are used clinically: ribavirin, mizoribine, and mycophenolate mofetil.
  • Ribavirin and mizoribine are prodrugs that are phosphorylated intracellularly to produce IMP analogs ( Goldstein et al., Cuff Med Chem, 6:519-536 (1999 )). Viramidine is a prodrug of Ribavirin. Mycophenolate mofetil is immunosuppressive, and has gastrointestinal irritative properties that may be attributable to its enterohepatic recirculation ( Papageorgiou C., Mini Rev Med Chem., 1:71-77 (2001 )). Mizoribine aglycone, a prodrug, is used as an IMPDH inhibitor. Other non-limiting examples IMPDH inhibitors, including prodrugs of mizoribine and mizoribine aglycone are known and are disclosed in published U.S. Patent application No. 20050004144 .
  • salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, ⁇ -ketoglutarate, and ⁇ -glycerophosphate.
  • Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
  • salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
  • a sufficiently basic compound such as an amine
  • a suitable acid affording a physiologically acceptable anion.
  • Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
  • the compounds (conjugates) of the invention can be prepared using standard synthetic methods known in the art.
  • a general ester synthesis is illustrated below:
  • the compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
  • the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
  • a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier.
  • the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 0.1% of active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form.
  • the amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
  • the tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
  • a liquid carrier such as a vegetable oil or a polyethylene glycol.
  • any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and devices.
  • the active compound may also be administered intravenously or intraperitoneally by infusion or injection.
  • Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
  • the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
  • the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
  • the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
  • the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
  • Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like.
  • Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
  • Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use.
  • the resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
  • Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
  • Examples of useful dermatological compositions which can be used to deliver the compounds of formula I to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392 ), Geria (U.S. Pat. No. 4,992,478 ), Smith et al. (U.S. Pat. No. 4,559,157 ) and Wortzman (U.S. Pat. No. 4,820,508 ).
  • Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949 .
  • the concentration of the compound(s) of formula I in a liquid composition will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%.
  • concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.
  • the amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
  • a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.
  • the compound is conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form.
  • the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about 75 ⁇ M, preferably, about 1 to 50 ⁇ M, most preferably, about 2 to about 30 ⁇ M. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the active ingredient. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s).
  • the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
  • the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
  • TLR agonist The ability of a compound of the invention to act as a TLR agonist may be determined using pharmacological models which are well known to the art, including the procedures disclosed by Lee et al.; PNAS, 100 p6646-6651, 2003 .
  • Sodium salt of 2-methoxyethanol is generated by dissolving sodium metal (81 mg) in 2-methoxyethanol (30 mL) with heat. To this solution is added the product of example 2 (1.0 g) dissolved in methoxyethanol (300 mL, with heat). The reaction mixture is heated for 8 h at 115 °C bath temperature, concentrated in vacuo to near dryness and the residue partitioned between ethyl acetate and water. Flash silica gel chromatography of the organic layer using 5% methanol in dichloromethane gave 763 mg product. NMR is consistent with structure assignment.
  • This reducing agent used to convert the nitrile to the aldehyde function is prepared essentially as described in Bull. Korean Chem. Soc. (2002), 23(12), 1697-1698 .
  • a 0.5 M solution in dry THF is prepared.
  • Example 7 The product of example 7 (800 mg) is combined with sodium iodide (504 mg) and acetonitrile (40 mL), and then chlorotrimethylsilane (0.5 mL) is slowly added. The mixture is heated at 70 °C for 3.5 h, cooled and filtered. The solid product is washed with water, then ether to yield 406 mg. NMR, UV, MS are consistent with structure assignment. This material is suitable for conjugation reactions between linkers and auxiliary groups.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Claims (32)

  1. Eine Verbindung mit der Formel (IA):
    Figure imgb0014
    wobei X1 -O-, -S- oder -NRc- ist;
    wobei Rc Wasserstoff, (C1-C10)Alkyl, oder substitutiertes (C1-C10)Alkyl oder Rc und R1 zusammen mit dem Stickstoffatom einen heterozyklischen Ring oder einen substituierten heterozyklischen Ring bilden kann, wobei die Substituenten an den Alkyl-, Aryl- oder heterozyklischen Gruppen Hydroxy, (C1-C6)Alkyl, Hydroxy(C1-C6)alkylen, (C1-C6)Alkoxy, (C3-C6)Cycloalkyl, (C1-C6)Alkoxy(C1-C6)alkylen, Amino, Cyano, Halogen oder Aryl ist;
    R1 Wasserstoff, (C1-C10)Alkyl, substituiertes (C1-C10)Alkyl, (C6-C10)Aryl oder substituiertes (C6-C10)Aryl, (C5-C9)heterozyklisch, substituiert (C5-C9)heterozyklisch ist; wobei die Substituenten an den Alkyl-, Aryl- oder heterozyklischen Gruppen Hydroxy, (C1-C6)Alkyl, Hydroxy(C1-C6)alkylen, (C1-C6)Alkoxy, (C3-C6)Cycloalkyl, (C1-C6)Alkoxy(C1-C6)alkylen, Amino, Cyano, Halogen oder Aryl sind;
    jeder R2 unabhängig Wasserstoff, -OH, (C1-C6)Alkyl, substituiertes (C1-C6)Alkyl, (C1-C6)Alkoxy, substituiertes (C1-C6)Alkoxy, -C(O)-(C1-C6)Alkyl(alkanoyl), substituiertes -C(O)-(C1-C6)Alkyl, -C(O)-(C6-C10)Aryl(aroyl), substituiertes -C(O)-(C6-C10)Aryl, -C(O)OH(Carboxyl), -C(O)O(C1-C6)Alkyl(alkoxycarbonyl), substituiertes -C(O)O(C1-C6)Alkyl, -NRaRb, -C(O)NRaRb(Carbamoyl), substituiertes -C(O)NRaRb, Halo, Nitro, oder Cyano ist; wobei die Substituenten an den Alkyl-, Aryl- oder heterozyklischen Gruppen Hydroxy, (C1-C6)Alkyl, Hydroxy(C1-C6)alkylen, (C1-C6)Alkoxy, (C3-C6)Cycloalkyl, (C1-C6)Alkoxy(C1-C6)alkylen, Amino, Cyano, Halogen oder Aryl sind; und n 1, 2, 3 oder 4 ist;
    jedes von Ra und Rb unabhängig voneinander Wasserstoff, (C1-C6)Alkyl, (C3-C8)Cycloalkyl, (C1-C6)Alkoxy, HalO(C1-C6)alkyl, (C3-C8)Cycloalkyl(C1-C6)alkyl, (C1-C6)Alkanoyl, Hydroxy(C1-C6)alkyl, Aryl, Aryl(C1-C6)alkyl, Het, Het(C1-C6)alkyl oder (C1-C6)Alkoxycarbonyl ist;
    X2 eine Bindung oder eine Linker-Gruppe ist; und R3 ein Protein oder ein Peptid ist;
    oder ein pharmazeutisch akzeptables Salz davon.
  2. Die Verbindung nach Anspruch 1, wobei X1 ein Schwefelatom ist.
  3. Die Verbindung nach Anspruch 1, wobei X1 ein Sauerstoffatom ist.
  4. Die Verbindung nach Anspruch 1, wobei X1 -NRc- ist, wobei Rc Wasserstoff, (C1-C6)Alkyl oder substituiertes (C1-C6)Alkyl ist;
    wobei die Alkyl-Substituenten (C3-C6)Cycloalkyl, Hydroxy, (C1-C6)Alkoxy, Amino, Cyano oder Aryl sind.
  5. Die Verbindung nach Anspruch 4, wobei X1 -NH- ist.
  6. Die Verbindung nach einem der Ansprüche 1-5, wobei R1 und Rc gemeinsam einen heterozyklischen Ring oder einen substituierten heterozyklischen Ring bilden.
  7. Die Verbindung nach Anspruch 6, wobei R1 und Rc zusammen einen substituierten oder unsubstituierten Morpholino-, Piperidino-, Pyrrolidino- oder Piperazino-Ring bilden.
  8. Die Verbindung nach einem der Ansprüche 1-7, wobei R1 Wasserstoff, (C1-C4)Alkyl oder substituiertes (C1-C4)Alkyl ist.
  9. Die Verbindung nach Anspruch 8, wobei R1 Wasserstoff, CH3-, CH3-CH2-, CH3CH2CH2-, Hydroxy(C1-C4)alkylen oder (C1-C4)Alkoxy(C1-C4)alkylen ist.
  10. Die Verbindung nach Anspruch 9, wobei R1 Wasserstoff, CH3-, CH3-CH2-, CH3-O-CH2CH2- oder CH3-CH2-O-CH2CH2- ist.
  11. Die Verbindung nach einem der Ansprüche 1-10, wobei R2 Wasserstoff, Halogen oder (C1-C4)Alkyl ist.
  12. Die Verbindung nach Anspruch 11, wobei R2 Wasserstoff, Chlor, Brom, CH3- oder CH3-CH2- ist.
  13. Die Verbindung nach einem der Ansprüche 1-12, wobei die Substituenten der an den Alkyl-, Aryl- oder heterozyklischen Gruppen Hydroxy, (C1-C6)Alkyl, Hydroxy(C1-C6)alkylen, (C1-C6)Alkoxy, (C1-C6)Alkoxy(C1-C6)alkylen, (C3-C6)Cycloalkyl, Amino, Cyano, Halogen oder Aryl sind.
  14. Die Verbindung nach einem der Ansprüche 1-13, wobei X2 eine Bindung oder eine Kette mit bis zu ungefähr 24 Atomen ist, wobei die Atome aus der Gruppe bestehend aus Kohlenstoff, Stickstoff, Schwefel, Nicht-Peroxidsauerstoff und Phosphor ausgewählt sind.
  15. Die Verbindung nach Anspruch 14, wobei X2 eine Bindung oder eine Kette mit ungefähr 4 bis ungefähr 12 Atomen ist.
  16. Die Verbindung nach Anspruch 14, wobei X2 eine Bindung oder eine Kette mit ungefähr 6 bis ungefähr 9 Atomen ist.
  17. Die Verbindung nach Anspruch 14, wobei X2
    Figure imgb0015
     ist.
  18. Die Verbindung nach einem der Ansprüche 1-17, wobei R3 ein Peptid ist.
  19. Die Verbindung nach Anspruch 18, wobei das Peptid 2 bis ungefähr 200 Aminosäurenreste aufweist.
  20. Die Verbindung nach Anspruch 19, wobei das Peptid 10 bis ungefähr 200 Aminosäurereste aufweist.
  21. Eine pharmazeutische Zusammensetzung, umfassend eine Verbindung nach einem der Ansprüche 1-20 und einen pharmazeutischen akzeptablen Träger.
  22. Die Verbindung nach einem der Ansprüche 1-20 zur Verwendung in der Vorbeugung oder Behandlung eines pathologischen Zustands oder Symptoms in einem Säugetier, wobei die Aktivität von TLR-Rezeptoren beteiligt ist und ein Agonismus einer solchen Aktivität gewünscht ist, in einem Säugetier mit Bedarf daran.
  23. Die Verbindung nach Anspruch 22, wobei der Zustand oder das Symptom Krebs, eine bakterielle Erkrankung, eine virale Erkranung, eine Autoimmunerkrankung oder Morbus Crohn ist.
  24. Die Verbindung nach Anspruch 23, wobei das Bakterium Bacillus anthracis (Milzbrand), Listeria monocytogenes, Francisella tularensis oder Salmonella ist.
  25. Die Verbindung nach Anspruch 24, wobei die Salmonella typhimurium oder enteritidis ist.
  26. Die Verbindung nach Anspruch 23, wobei das Virus ein RNA-Virus, ein Produkt des RNA-Virus oder ein DNA-Virus ist.
  27. Die Verbindung nach Anspruch 26, wobei das DNA-Virus das Hepatitis B-Virus ist.
  28. Die Verbindung nach 23, wobei die Krebserkrankung eine Interferonsensitive Krebserkrankung, wie z.B. eine Leukämie, ein Lymphom, ein Myelom, ein Melanom oder ein Nierenkrebs ist.
  29. Eine Verbindung nach einem der Ansprüche 1-20, zur Verwendung in einer meidzinischen Therapie.
  30. Die Verbindung nach Anspruch 29, wobei die medizinische Therapie die Behandlung von Krebs, einer bakteriellen Erkrankung, einer viralen Erkrankung, einer Autoimmunerkrankung oder Morbus Crohn ist.
  31. Verbindung nach einem der Ansprüche 1-20 zur Verwendung bei der Behandlung von Krebs, einer bakteriellen Erkrankung, einer viralen Erkrankung, einer Autoimmunerkrankung oder Morbus Crohn.
  32. Verbindung nach Anspruch 31, wobei die Verbindung in einer Zusammensetzung, die auch einen pharmazeutisch akzeptablen Träger enthält, bereitgestellt wird.
EP06813535.9A 2005-08-22 2006-08-21 Tlr-agonisten Not-in-force EP1931352B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71033705P 2005-08-22 2005-08-22
PCT/US2006/032371 WO2007024707A2 (en) 2005-08-22 2006-08-21 Tlr agonists

Publications (3)

Publication Number Publication Date
EP1931352A2 EP1931352A2 (de) 2008-06-18
EP1931352A4 EP1931352A4 (de) 2011-11-23
EP1931352B1 true EP1931352B1 (de) 2016-04-13

Family

ID=37772216

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06813535.9A Not-in-force EP1931352B1 (de) 2005-08-22 2006-08-21 Tlr-agonisten

Country Status (7)

Country Link
US (2) US20090324551A1 (de)
EP (1) EP1931352B1 (de)
JP (2) JP2009504803A (de)
CN (1) CN101304748A (de)
CA (1) CA2620182A1 (de)
ES (1) ES2577514T3 (de)
WO (1) WO2007024707A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4768263B2 (ja) * 2002-09-27 2011-09-07 大日本住友製薬株式会社 新規アデニン化合物及びその用途
AU2005226359B2 (en) * 2004-03-26 2011-02-03 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
EP1931352B1 (de) 2005-08-22 2016-04-13 The Regents of The University of California Tlr-agonisten
JPWO2007034817A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
EP2029597A4 (de) * 2006-05-31 2011-11-23 Univ California Purinanaloga
WO2008004948A1 (en) 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
PL2510946T3 (pl) 2007-02-07 2015-12-31 Univ California Koniugaty syntetycznych agonistów tlr i ich zastosowania
AR065372A1 (es) * 2007-02-19 2009-06-03 Smithkline Beecham Corp Derivados de purina
WO2008114006A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
PT2132209E (pt) * 2007-03-19 2014-04-15 Astrazeneca Ab Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
EP2138497A4 (de) * 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co Neue adeninverbindung
PL2155743T3 (pl) * 2007-05-08 2013-01-31 Astrazeneca Ab Imidazochinoliny o właściwościach immunomodulacyjnych
PT2170888E (pt) * 2007-06-29 2015-08-21 Gilead Sciences Inc Purina derivados e sua utilização como moduladores de recetor de tipo toll 7
WO2009034386A1 (en) * 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
US20110054168A1 (en) * 2008-01-17 2011-03-03 Ayumu Kurimoto Method for preparing adenine compound
EP2246353A4 (de) * 2008-01-17 2011-04-20 Dainippon Sumitomo Pharma Co Verfahren zur herstellung einer adeninverbindung
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
PT2364314E (pt) 2008-12-09 2014-06-09 Gilead Sciences Inc Moduladores de recetores toll-like
US20110293565A1 (en) * 2009-01-30 2011-12-01 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
BRPI1008383A2 (pt) 2009-02-11 2016-02-23 Univ California composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
AU2010310813B2 (en) * 2009-10-22 2015-06-18 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011068233A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2011079016A1 (en) * 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US9173935B2 (en) 2010-04-30 2015-11-03 Telormedix Sa Phospholipid drug analogs
US20120003298A1 (en) * 2010-04-30 2012-01-05 Alcide Barberis Methods for inducing an immune response
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
MX2012013713A (es) 2010-05-26 2013-01-28 Selecta Biosciences Inc Composiciones de nanovehiculos con adyuvante no acoplado.
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
WO2012080728A1 (en) 2010-12-16 2012-06-21 Astrazeneca Ab Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy
ES2627433T3 (es) 2010-12-17 2017-07-28 Sumitomo Dainippon Pharma Co., Ltd. Derivados de purina
US20120231023A1 (en) * 2011-03-08 2012-09-13 Baylor Research Institute Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
KR20140071340A (ko) * 2011-07-22 2014-06-11 파웰 카린스키 종양 선택적 케모카인 조절
WO2013014052A1 (en) 2011-07-22 2013-01-31 Glaxosmithkline Llc Composition
NZ704224A (en) 2012-08-24 2018-04-27 Glaxosmithkline Llc Pyrazolopyrimidine compounds
WO2014052828A1 (en) 2012-09-27 2014-04-03 The Regents Of The University Of California Compositions and methods for modulating tlr4
MX358025B (es) 2012-11-20 2018-08-02 Glaxosmithkline Llc Star Compuestos novedosos.
CN104780923B (zh) 2012-11-20 2017-03-15 葛兰素史克有限责任公司 干扰素诱导剂化合物
ES2632448T3 (es) 2012-11-20 2017-09-13 Glaxosmithkline Llc Nuevos compuestos
WO2014131023A1 (en) * 2013-02-25 2014-08-28 The Scripps Research Institute Neoseptins: small molecule adjuvants
NZ728072A (en) 2014-07-11 2018-06-29 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
EP3177601B1 (de) * 2014-08-06 2023-03-01 The Scripps Research Institute Tlr-abhängige kleinmolekülige adjuvantien
CN110938076B (zh) * 2014-08-15 2021-08-10 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CA2960436C (en) 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
AU2016349080B2 (en) 2015-11-05 2019-03-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554550A1 (de) 2016-12-13 2019-10-23 Bolt Biotherapeutics, Inc. Antikörper-adjuvans-konjugate
WO2018112223A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
EP4218824A3 (de) 2017-04-14 2023-08-09 Bolt Biotherapeutics, Inc. Verfahren zur immunkonjugatsynthese
JP2021035910A (ja) * 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
WO2019196918A1 (zh) * 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
US20210154316A1 (en) 2018-05-17 2021-05-27 Bolt Biotherapeutics, Inc. Immunoconjugates
CN109608462B (zh) * 2018-12-15 2021-11-23 华南理工大学 一种7-烃基-9-烷氧/硫基嘌呤-8-酮类化合物及其合成方法与在药物中的应用
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2021046347A1 (en) 2019-09-04 2021-03-11 Bolt Biotherapeutics, Inc. Immunoconjugate synthesis method
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
AU2021300632A1 (en) 2020-07-02 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of achieving HIV viral remission using long-acting antiretroviral agents
CN114315861A (zh) * 2020-09-27 2022-04-12 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
EP4232094A1 (de) 2020-10-21 2023-08-30 Univerza V Ljubljani Konjugierte tlr7- und nod2-agonisten
CN115819215A (zh) * 2022-11-08 2023-03-21 广东省科学院化工研究所 一种路易斯酸催化合成羧酸衍生物的方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
EP0553202B1 (de) 1990-10-05 1995-04-12 Minnesota Mining And Manufacturing Company Verfahren zur herstellung von imidazo[4,5-c]chinolin-4-aminen
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
DE19637209B4 (de) * 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
ES2290969T3 (es) 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
DK0957929T3 (da) 1996-10-25 2006-07-03 Gilead Sciences Inc Vaskulær endotelial vækstfaktor (VEGF) nukleinsyreligandkomplekser
JPH10298181A (ja) 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
KR100540046B1 (ko) * 1997-11-12 2006-01-10 미쓰비시 가가꾸 가부시키가이샤 퓨린유도체 및 이를 유효성분으로 함유하는 의약
DE69817393T2 (de) * 1997-11-28 2004-06-17 Sumitomo Pharmaceuticals Co., Ltd. Neue heterozyklische verbindungen
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
CN1555264A (zh) * 1999-01-08 2004-12-15 3M 用于治疗粘膜病症的含咪喹莫特或其它免疫应答调节剂的制剂
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
CA2394646A1 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel purines
DE60031886T2 (de) 1999-12-17 2007-09-06 Ariad Pharmaceuticals, Inc., Cambridge Purinderivate
CA2396276A1 (en) * 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
US6733764B2 (en) * 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
EP1328806A2 (de) * 2000-09-15 2003-07-23 Virco N.V. System und methode zur optimierung der medikamentösen therapie in der behandlung von krankheiten
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
ES2278016T3 (es) * 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
WO2002085905A1 (fr) * 2001-04-17 2002-10-31 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives d'adenine
JP4358521B2 (ja) 2001-05-18 2009-11-04 サーナ・セラピューティクス・インコーポレイテッド 細胞デリバリーのためのコンジュゲートおよび組成物
EP1401837B1 (de) 2001-06-29 2005-10-19 Cv Therapeutics, Inc. Purin derivate als a2b adenosin rezeptor antagonisten
JP4397691B2 (ja) * 2001-10-30 2010-01-13 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
GB0206461D0 (en) 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
US7427629B2 (en) * 2002-08-15 2008-09-23 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
JP4768263B2 (ja) * 2002-09-27 2011-09-07 大日本住友製薬株式会社 新規アデニン化合物及びその用途
JP2004137157A (ja) 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
WO2005020892A2 (en) * 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
KR20060096415A (ko) * 2003-09-05 2006-09-11 애나디스 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스에 의한 감염증을 치료하기 위해투여하는 ｔｌｒ７ 리간드 및 이의 전구약물
JP2005089334A (ja) * 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
US7138401B2 (en) * 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
CA2558263A1 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
AU2005226359B2 (en) 2004-03-26 2011-02-03 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
JPWO2005092892A1 (ja) 2004-03-26 2008-02-14 大日本住友製薬株式会社 ８−オキソアデニン化合物
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
PL1819230T3 (pl) 2004-12-07 2013-02-28 Univ Miami Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia
WO2006100226A1 (en) 2005-03-21 2006-09-28 Ferrer Internacional, S. A. Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
EP1931352B1 (de) 2005-08-22 2016-04-13 The Regents of The University of California Tlr-agonisten
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
JPWO2007034817A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
BRPI0616770A2 (pt) 2005-09-27 2011-06-28 Coley Pharm Gmbh modulação de respostas imunes mediadas por tlr empregando oligonucleotìdeos adaptadores
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
EP2029597A4 (de) 2006-05-31 2011-11-23 Univ California Purinanaloga
WO2008005555A1 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US7919490B2 (en) * 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
PL2510946T3 (pl) 2007-02-07 2015-12-31 Univ California Koniugaty syntetycznych agonistów tlr i ich zastosowania
PT2170888E (pt) * 2007-06-29 2015-08-21 Gilead Sciences Inc Purina derivados e sua utilização como moduladores de recetor de tipo toll 7
CA2702644A1 (en) 2007-10-16 2009-04-23 Gilead Palo Alto, Inc. A3 adenosine receptor antagonists
US20090202626A1 (en) 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
BRPI1008383A2 (pt) 2009-02-11 2016-02-23 Univ California composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
AU2010310813B2 (en) 2009-10-22 2015-06-18 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20120003298A1 (en) 2010-04-30 2012-01-05 Alcide Barberis Methods for inducing an immune response
US9173935B2 (en) 2010-04-30 2015-11-03 Telormedix Sa Phospholipid drug analogs
US20130202629A1 (en) 2010-04-30 2013-08-08 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Also Published As

Publication number Publication date
JP2009504803A (ja) 2009-02-05
AU2006283524A1 (en) 2007-03-01
JP2013040209A (ja) 2013-02-28
AU2006283524A2 (en) 2008-06-05
CN101304748A (zh) 2008-11-12
WO2007024707A2 (en) 2007-03-01
EP1931352A4 (de) 2011-11-23
ES2577514T3 (es) 2016-07-15
US20130165455A1 (en) 2013-06-27
US9359360B2 (en) 2016-06-07
CA2620182A1 (en) 2007-03-01
WO2007024707A3 (en) 2007-09-20
EP1931352A2 (de) 2008-06-18
US20090324551A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
EP1931352B1 (de) Tlr-agonisten
US8846697B2 (en) Purine analogs
CN109311851B (zh) 二氢嘧啶基苯并氮杂䓬甲酰胺化合物
ES2456964T3 (es) Conjugados de agonistas de TLR sintéticos y usos de los mismos
CN111527088B (zh) 作为激酶抑制剂的氨基-甲基哌啶衍生物
US20180134701A1 (en) Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds
EA023556B1 (ru) 1,2-дизамещенные-4-аминоимидазохинолины
RO119413B1 (ro) Derivaţi izosteri ai substratului aspartat proteazei, sărurile lor, compoziţii farmaceutice şi utilizare
EA019749B1 (ru) Противовирусные соединения
MX2007007228A (es) Profarmaco de amida de gemcitabina, composiciones y uso del mismo.
JP2003520783A (ja) ウイルス感染を二重ターゲティングおよびガン細胞をターゲティングするための組成物および方法
BG64179B1 (bg) Ациклични нуклеозидни производни
US9133203B2 (en) Pyrroloquinazoline compounds
AU2006283524B2 (en) TLR agonists
US6440946B1 (en) Multiple-agents-binding compound, production and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080319

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHAN, MICHAEL

Inventor name: COTTAM, HOWARD, B.

Inventor name: WU, CHRISTINA, C., N.

Inventor name: CARSON, DENNIS, A.

Inventor name: TAKABAYASHI, KENJI

A4 Supplementary search report drawn up and despatched

Effective date: 20111024

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/522 20060101AFI20111019BHEP

Ipc: C07D 473/10 20060101ALI20111019BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130924

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150924

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CARSON, DENNIS A.

Inventor name: COTTAM, HOWARD B.

Inventor name: TAKABAYASHI, KENJI

Inventor name: WU, CHRISTINA C. N.

Inventor name: CHAN, MICHAEL

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

INTG Intention to grant announced

Effective date: 20160224

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 789353

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160415

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006048716

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: RIEDERER HASLER AND PARTNER PATENTANWAELTE AG, LI

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2577514

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20160715

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 789353

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160413

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160714

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006048716

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006048716

Country of ref document: DE

26N No opposition filed

Effective date: 20170116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20160821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160821

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160821

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170301

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160821

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060821

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20181203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160822